Status:
ENROLLING_BY_INVITATION
Impact of SGLT2 Inhibitors in Heart Transplant Recipients
Lead Sponsor:
Universidade Federal do Ceara
Collaborating Sponsors:
Hospital de Messejana
Conditions:
Transplant; Failure, Heart
Cardiac Allograft Vasculopathy
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The goal of this clinical trial is to test if SGLT2 inhibitors could prevent or delay the development of Cardiac Allograft Vasculopathy (CAV) post-heart transplantation (TxC). The main questions it ai...
Eligibility Criteria
Inclusion
- Patients of both sexes, aged ≥ 18 years, who have undergone heart transplantation between January 2017 and December 2023 and are under the care of the Heart Transplant and Heart Failure Unit at Hospital de Messejana.
Exclusion
- Patients who refuse to participate in the study, those with known hypersensitivity or intolerance to iSGLT2, individuals with type 1 diabetes mellitus, symptoms of hypotension, or systolic blood pressure below 80 mm Hg, an estimated glomerular filtration rate (eGFR) below 20 ml per minute per 1.73 m2 of body surface area, and pregnant women
Key Trial Info
Start Date :
November 20 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06147271
Start Date
November 20 2023
End Date
August 1 2025
Last Update
May 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Messejana Hospital
Fortaleza, Ceará, Brazil